Publications by authors named "A Banner"

Background: The climate crisis and depleting fossil fuel reserves have led to a drive for 'green' alternatives to the way we manufacture chemicals, and the formation of a bioeconomy that reduces our reliance on petrochemical-based feedstocks. Advances in Synthetic biology have provided the opportunity to engineer micro-organisms to produce compounds from renewable feedstocks, which could play a role in replacing traditional, petrochemical based, manufacturing routes. However, there are few examples of bio-manufactured products achieving commercialisation.

View Article and Find Full Text PDF
Article Synopsis
  • Enfortumab vedotin (EV) is a new treatment option for patients with advanced urothelial carcinoma who haven't responded to other therapies.
  • A study involving 128 patients in Austria showed an objective response rate of 31%, with median progression-free survival of 4.8 months and overall survival of 10.75 months.
  • The treatment was found to be feasible and effective, with an acceptable safety profile, although lower efficacy was noted compared to earlier trials, likely due to the patient population being in later therapy lines.
View Article and Find Full Text PDF